Atlas Trials

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Clinical trial NCT02627963 · COMPLETED

Trial details

NCT number
NCT02627963
Sponsor
AVEO Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Carcinoma, Renal Cell
Start date
2016-05-24
Primary completion
2018-10-04
Enrollment
350

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.